0001209191-24-000790.txt : 20240104
0001209191-24-000790.hdr.sgml : 20240104
20240104163010
ACCESSION NUMBER: 0001209191-24-000790
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Masoud Maher
CENTRAL INDEX KEY: 0001874571
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 24512354
MAIL ADDRESS:
STREET 1: C/O MAXCYTE, INC.
STREET 2: 22 FIRSTFIELD ROAD, SUITE 110
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-03
0
0001287098
MAXCYTE, INC.
MXCT
0001874571
Masoud Maher
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
1
1
0
0
President and CEO
0
Employee Stock Option (right to buy)
4.42
2024-01-03
4
A
0
400000
0.00
A
2034-01-02
Common Stock
400000
400000
D
This option grant was made pursuant to the terms of the letter agreement, dated as of December 11, 2023, by and between the Issuer and the reporting person, entered into in connection with his appointment as President and Chief Executive Officer of the Issuer, as set forth in a Current Report on Form 8-K filed by the Issuer on December 11, 2023. Of the shares underlying the option, 25% will vest on January 2, 2025 and the remaining 75% will vest in 36 equal monthly installments thereafter, in each case subject to the reporting person's continuous service with the Issuer at the applicable vesting date.
/s/ Katie Kazem, Attorney-in-Fact
2024-01-04